RhumbLine Advisers’s Perspective Therapeutics CATX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$372K Buy
135,118
+11,819
+10% +$35.8K ﹤0.01% 2906
2026
Q2
$420K Buy
123,299
+46,209
+60% +$175K ﹤0.01% 2875
2026
Q1
$321K Buy
77,090
+519
+0.7% +$2.19K ﹤0.01% 2882
2025
Q4
$211K Sell
76,571
-8,234
-10% -$23.5K ﹤0.01% 3158
2025
Q3
$291K Buy
84,805
+1,555
+2% +$5.67K ﹤0.01% 3021
2025
Q2
$286K Sell
83,250
-14,912
-15% -$39.4K ﹤0.01% 3011
2025
Q1
$209K Buy
98,162
+3,170
+3% +$9.5K ﹤0.01% 3082
2024
Q4
$303K Buy
94,992
+4,075
+4% +$33.3K ﹤0.01% 2979
2024
Q3
$1.21M Buy
90,917
+27,747
+44% +$369K ﹤0.01% 2164
2024
Q2
$630K Buy
+63,170
New +$913K ﹤0.01% 2508

Other funds holding CATX

RhumbLine Advisers's CATX Position: Q3 2026 in Review

RhumbLine Advisers increased its Perspective Therapeutics (CATX) stake by 9.6% in Q3 2026, buying an estimated $35.8K and bringing the position to 135,118 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #2906.

RhumbLine Advisers first reported a position in CATX in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.21M in Q3 2024. 120 funds tracked by Wall St. Rank hold CATX as of Q3 2026.

  • RhumbLine Advisers held 135,118 shares of Perspective Therapeutics worth $372K as of Q3 2026.
  • RhumbLine Advisers bought 11,819 Perspective Therapeutics shares in Q3 2026, an estimated $35.8K.
  • Perspective Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2906 holding.
  • RhumbLine Advisers first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • RhumbLine Advisers's Perspective Therapeutics position peaked at $1.21M in Q3 2024.
  • 120 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.